Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15

Yoshiro Saikawa, Tsudoi Sugiura, Fumiki Toriumi, Tetsuro Kubota, Kazuhiro Suganuma, Soichiro Isshiki, Yoshihide Otani, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Drug resistance to cisplatin (CDDP) would represent a major obstacle for cancer therapy. The adenosine tnphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. The purpose of the present study was to investigate the relationship between cyclooxygenase-2 (COX-2) expression and the level of chemosensitivity to CDDP. We established the COX-2-overexpressed colon cancer cell line TR-5 from HCT-15 cells. We quantified the expression of m-RNA for MRP-1 and MDR-1 by a real-time PCR method, determining that the values of each gene/standardized GAPDH in HCT-15 and TR-5 were 2.3±0.4 and 6.1±0.5 in MRP-1 (p<0.02) and 9.0±4.8 and 3.6±0.5 in MDR-1, respectively. With respect to chemosensitivity, survival rates for 3 μg/ml and 10 μg/ml of CDDP were 81.5±12.2% and 26.1±11.7% (IC50=6.5 μ/ml) for HCT-15 and 96.6±1.7% and 77.4±4.9% (IC50=18.5 μ/ml) for TR-5, respectively, thus TR-5 showed higher resistance to CDDP than HCT-15 did with statistical differences. We also demonstrated a successful re-sensitization to CDDP toxicity in TR-5 by means of the COX-2 selective inhibitor JTE-522, 4-(4-cyclohexyl-2-methyl-1, 3-oxazol-5-yl)-2-fluorobenzene sulfonamide, which markedly decreased the IC50 of CDDP for TR-5 (from 17.3±2.6 μ/ml to 8.6±2.5 μ/ml). In conclusion, COX-2 overexpression induced increased MRP-1 expression in a colon cancer cell line, TR-5, resulting in chemoresistance to CDDP that was approximately triple the level of chemoresistance observed in the anginal HCT-15 cells line, as measured by calculation of the IC50. We also confirmed the efficacy of pretreatment of TR-5 cells with the COX-2 selective inhibitor JTE-522 in restoring chemosensitivity of these cells to CDDP, suggesting a strategy for overcoming drug resistance to CDDP.

Original languageEnglish
Pages (from-to)2723-2728
Number of pages6
JournalAnticancer Research
Volume24
Issue number5 A
Publication statusPublished - 2004 Sep

Fingerprint

Cyclooxygenase 2
Colonic Neoplasms
Inhibitory Concentration 50
Cell Line
Cyclooxygenase 2 Inhibitors
Drug Resistance
Genes
Fluorobenzenes
MDR Genes
Multidrug Resistance-Associated Proteins
Sulfonamides
Multiple Drug Resistance
P-Glycoprotein
Adenosine
Cisplatin
Real-Time Polymerase Chain Reaction
Carrier Proteins
RNA
multidrug resistance-associated protein 1
Neoplasms

Keywords

  • Cisplatin
  • Colon cancer cell
  • Cyclooxygenase-2
  • MDR-1
  • MRP-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saikawa, Y., Sugiura, T., Toriumi, F., Kubota, T., Suganuma, K., Isshiki, S., ... Kitajima, M. (2004). Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Research, 24(5 A), 2723-2728.

Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. / Saikawa, Yoshiro; Sugiura, Tsudoi; Toriumi, Fumiki; Kubota, Tetsuro; Suganuma, Kazuhiro; Isshiki, Soichiro; Otani, Yoshihide; Kumai, Koichiro; Kitajima, Masaki.

In: Anticancer Research, Vol. 24, No. 5 A, 09.2004, p. 2723-2728.

Research output: Contribution to journalArticle

Saikawa, Y, Sugiura, T, Toriumi, F, Kubota, T, Suganuma, K, Isshiki, S, Otani, Y, Kumai, K & Kitajima, M 2004, 'Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15', Anticancer Research, vol. 24, no. 5 A, pp. 2723-2728.
Saikawa Y, Sugiura T, Toriumi F, Kubota T, Suganuma K, Isshiki S et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Research. 2004 Sep;24(5 A):2723-2728.
Saikawa, Yoshiro ; Sugiura, Tsudoi ; Toriumi, Fumiki ; Kubota, Tetsuro ; Suganuma, Kazuhiro ; Isshiki, Soichiro ; Otani, Yoshihide ; Kumai, Koichiro ; Kitajima, Masaki. / Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. In: Anticancer Research. 2004 ; Vol. 24, No. 5 A. pp. 2723-2728.
@article{104d08c848f44a399616cbbeac2b0cd8,
title = "Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15",
abstract = "Drug resistance to cisplatin (CDDP) would represent a major obstacle for cancer therapy. The adenosine tnphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. The purpose of the present study was to investigate the relationship between cyclooxygenase-2 (COX-2) expression and the level of chemosensitivity to CDDP. We established the COX-2-overexpressed colon cancer cell line TR-5 from HCT-15 cells. We quantified the expression of m-RNA for MRP-1 and MDR-1 by a real-time PCR method, determining that the values of each gene/standardized GAPDH in HCT-15 and TR-5 were 2.3±0.4 and 6.1±0.5 in MRP-1 (p<0.02) and 9.0±4.8 and 3.6±0.5 in MDR-1, respectively. With respect to chemosensitivity, survival rates for 3 μg/ml and 10 μg/ml of CDDP were 81.5±12.2{\%} and 26.1±11.7{\%} (IC50=6.5 μ/ml) for HCT-15 and 96.6±1.7{\%} and 77.4±4.9{\%} (IC50=18.5 μ/ml) for TR-5, respectively, thus TR-5 showed higher resistance to CDDP than HCT-15 did with statistical differences. We also demonstrated a successful re-sensitization to CDDP toxicity in TR-5 by means of the COX-2 selective inhibitor JTE-522, 4-(4-cyclohexyl-2-methyl-1, 3-oxazol-5-yl)-2-fluorobenzene sulfonamide, which markedly decreased the IC50 of CDDP for TR-5 (from 17.3±2.6 μ/ml to 8.6±2.5 μ/ml). In conclusion, COX-2 overexpression induced increased MRP-1 expression in a colon cancer cell line, TR-5, resulting in chemoresistance to CDDP that was approximately triple the level of chemoresistance observed in the anginal HCT-15 cells line, as measured by calculation of the IC50. We also confirmed the efficacy of pretreatment of TR-5 cells with the COX-2 selective inhibitor JTE-522 in restoring chemosensitivity of these cells to CDDP, suggesting a strategy for overcoming drug resistance to CDDP.",
keywords = "Cisplatin, Colon cancer cell, Cyclooxygenase-2, MDR-1, MRP-1",
author = "Yoshiro Saikawa and Tsudoi Sugiura and Fumiki Toriumi and Tetsuro Kubota and Kazuhiro Suganuma and Soichiro Isshiki and Yoshihide Otani and Koichiro Kumai and Masaki Kitajima",
year = "2004",
month = "9",
language = "English",
volume = "24",
pages = "2723--2728",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15

AU - Saikawa, Yoshiro

AU - Sugiura, Tsudoi

AU - Toriumi, Fumiki

AU - Kubota, Tetsuro

AU - Suganuma, Kazuhiro

AU - Isshiki, Soichiro

AU - Otani, Yoshihide

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2004/9

Y1 - 2004/9

N2 - Drug resistance to cisplatin (CDDP) would represent a major obstacle for cancer therapy. The adenosine tnphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. The purpose of the present study was to investigate the relationship between cyclooxygenase-2 (COX-2) expression and the level of chemosensitivity to CDDP. We established the COX-2-overexpressed colon cancer cell line TR-5 from HCT-15 cells. We quantified the expression of m-RNA for MRP-1 and MDR-1 by a real-time PCR method, determining that the values of each gene/standardized GAPDH in HCT-15 and TR-5 were 2.3±0.4 and 6.1±0.5 in MRP-1 (p<0.02) and 9.0±4.8 and 3.6±0.5 in MDR-1, respectively. With respect to chemosensitivity, survival rates for 3 μg/ml and 10 μg/ml of CDDP were 81.5±12.2% and 26.1±11.7% (IC50=6.5 μ/ml) for HCT-15 and 96.6±1.7% and 77.4±4.9% (IC50=18.5 μ/ml) for TR-5, respectively, thus TR-5 showed higher resistance to CDDP than HCT-15 did with statistical differences. We also demonstrated a successful re-sensitization to CDDP toxicity in TR-5 by means of the COX-2 selective inhibitor JTE-522, 4-(4-cyclohexyl-2-methyl-1, 3-oxazol-5-yl)-2-fluorobenzene sulfonamide, which markedly decreased the IC50 of CDDP for TR-5 (from 17.3±2.6 μ/ml to 8.6±2.5 μ/ml). In conclusion, COX-2 overexpression induced increased MRP-1 expression in a colon cancer cell line, TR-5, resulting in chemoresistance to CDDP that was approximately triple the level of chemoresistance observed in the anginal HCT-15 cells line, as measured by calculation of the IC50. We also confirmed the efficacy of pretreatment of TR-5 cells with the COX-2 selective inhibitor JTE-522 in restoring chemosensitivity of these cells to CDDP, suggesting a strategy for overcoming drug resistance to CDDP.

AB - Drug resistance to cisplatin (CDDP) would represent a major obstacle for cancer therapy. The adenosine tnphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. The purpose of the present study was to investigate the relationship between cyclooxygenase-2 (COX-2) expression and the level of chemosensitivity to CDDP. We established the COX-2-overexpressed colon cancer cell line TR-5 from HCT-15 cells. We quantified the expression of m-RNA for MRP-1 and MDR-1 by a real-time PCR method, determining that the values of each gene/standardized GAPDH in HCT-15 and TR-5 were 2.3±0.4 and 6.1±0.5 in MRP-1 (p<0.02) and 9.0±4.8 and 3.6±0.5 in MDR-1, respectively. With respect to chemosensitivity, survival rates for 3 μg/ml and 10 μg/ml of CDDP were 81.5±12.2% and 26.1±11.7% (IC50=6.5 μ/ml) for HCT-15 and 96.6±1.7% and 77.4±4.9% (IC50=18.5 μ/ml) for TR-5, respectively, thus TR-5 showed higher resistance to CDDP than HCT-15 did with statistical differences. We also demonstrated a successful re-sensitization to CDDP toxicity in TR-5 by means of the COX-2 selective inhibitor JTE-522, 4-(4-cyclohexyl-2-methyl-1, 3-oxazol-5-yl)-2-fluorobenzene sulfonamide, which markedly decreased the IC50 of CDDP for TR-5 (from 17.3±2.6 μ/ml to 8.6±2.5 μ/ml). In conclusion, COX-2 overexpression induced increased MRP-1 expression in a colon cancer cell line, TR-5, resulting in chemoresistance to CDDP that was approximately triple the level of chemoresistance observed in the anginal HCT-15 cells line, as measured by calculation of the IC50. We also confirmed the efficacy of pretreatment of TR-5 cells with the COX-2 selective inhibitor JTE-522 in restoring chemosensitivity of these cells to CDDP, suggesting a strategy for overcoming drug resistance to CDDP.

KW - Cisplatin

KW - Colon cancer cell

KW - Cyclooxygenase-2

KW - MDR-1

KW - MRP-1

UR - http://www.scopus.com/inward/record.url?scp=6444222237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444222237&partnerID=8YFLogxK

M3 - Article

C2 - 15517878

AN - SCOPUS:6444222237

VL - 24

SP - 2723

EP - 2728

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -